Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor to Participate at Upcoming Investor Conferences

Business Wire November 26, 2024

Xencor Reports Third Quarter 2024 Financial Results

Business Wire November 6, 2024

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Business Wire November 4, 2024

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Business Wire October 10, 2024

Xencor Announces Upcoming Change to Board of Directors

Business Wire October 4, 2024

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire September 12, 2024

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Business Wire September 11, 2024

Xencor Announces Proposed Public Offering of Common Stock

Business Wire September 10, 2024

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Business Wire September 9, 2024

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Business Wire September 6, 2024

Xencor Reports Second Quarter 2024 Financial Results

Business Wire August 5, 2024

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Business Wire June 13, 2024

Xencor Reports First Quarter 2024 Financial Results

Business Wire May 9, 2024

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Business Wire April 9, 2024

Xencor to Present at Upcoming Investor Conferences

Business Wire February 28, 2024

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 27, 2024

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Business Wire February 20, 2024

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2024

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Business Wire January 2, 2024

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire November 21, 2023